Related Experiment Video

Updated: Jun 18, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Angiogenesis inhibitors in the management of breast cancer

Verena Bossung1, Nadia Harbeck

  • 1Breast Center, Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany.

Current Opinion in Obstetrics & Gynecology
|December 3, 2009
PubMed
Abstract

Insights

Antiangiogenic therapies show promise for breast cancer treatment. Bevacizumab is approved for metastatic breast cancer, with other agents like multikinase inhibitors under investigation for improved efficacy and patient selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.
  • Antiangiogenic therapies target this process to inhibit tumor development.
  • Recent advancements have focused on novel agents for breast cancer treatment.

Purpose of the Study:

  • To review antiangiogenic agents evaluated in recent breast cancer clinical trials.
  • To highlight therapies with significant potential for future clinical application.
  • To discuss the role of angiogenesis inhibitors in breast cancer management.

Main Methods:

  • Review of recent clinical trials involving antiangiogenic agents in breast cancer.
  • Analysis of therapeutic agents demonstrating antitumor activity.
  • Evaluation of approved and investigational antiangiogenic drugs.

Main Results:

  • Bevacizumab, an angiogenesis inhibitor, is the first approved agent for metastatic breast cancer.
  • Multikinase inhibitors (sorafenib, sunitinib, pazopanib) show promising early results.
  • Predictive biomarkers are essential for optimizing efficacy and safety of antiangiogenic therapies.

Conclusions:

  • Novel antiangiogenic agents have shown positive outcomes in breast cancer trials.
  • Bevacizumab is approved for first-line metastatic breast cancer therapy.
  • Further research is needed to define the role of angiogenesis inhibitors in early breast cancer and for patient selection.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...